Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors

• A series of aralkyl diamine derivatives were designed and synthesized.
• Target compounds were tested for triple reuptake inhibition.
• Three lead compounds showed in vivo activities in the rat forced swim test.
• 36a displayed desirable pharmacokinetic properties, and acceptable safety profile.

A series of aralkyl diamine derivatives were designed, synthesized, and evaluated for their triple reuptake inhibitory abilities. Compounds 18c (5-HT, NE, DA, IC50 = 389, 69, 238 nM), 36a (5-HT, NE, DA, IC50 = 378, 477, 247 nM), and 36d (5-HT, NE, DA, IC50 = 501, 206, 357 nM) showed in vivo activities in the rat forced swim test at 5, 10, and 20 mg/kg PO. 36a was identified as the most promising candidate in this study. Specifically, 36a exhibited high selectivity for monoamine transporters over a number of CNS-related targets. Furthermore, 36a showed a good pharmacokinetic properties and acceptable safety profile in preclinical studies.

Figure optionsDownload as PowerPoint slide